![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Pharmacokinetics of Telaprevir and Selected ART Medications in HCV/HIV Coinfected Patients
|
|
|
Reported by Jules Levin
IDSA Oct 17-21 2012 San Diego
Joshua Henshaw1, Lisa Mahnke1, Bambang Adiwijaya1, Nathalie Adda1, Raymond Rubin1, Mark S. Sulkowski2, Varun Garg1*
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 2Johns Hopkins University School of Medicine, Baltimore, MD, USA
![IDSA1.gif](../images/101912/101912-2/IDSA1.gif)
![IDSA2.gif](../images/101912/101912-2/IDSA2.gif)
![IDSA3.gif](../images/101912/101912-2/IDSA3.gif)
![IDSA4.gif](../images/101912/101912-2/IDSA4.gif)
![IDSA5.gif](../images/101912/101912-2/IDSA5.gif)
![IDSA6.gif](../images/101912/101912-2/IDSA6.gif)
![IDSA7.gif](../images/101912/101912-2/IDSA7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|